Trial · NCT00549549
Results by group220
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 220
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Celecoxib 50 mg | Baseline | 3.03 | Standard Deviation 0.67 | Scores on a scale |
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Celecoxib 400/200 mg | Baseline | 2.73 | Standard Deviation 0.62 | Scores on a scale |
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Celecoxib 800/400 mg | Baseline | 2.84 | Standard Deviation 0.69 | Scores on a scale |
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Indomethacin 50 mg | Baseline | 2.83 | Standard Deviation 0.76 | Scores on a scale |
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Celecoxib 50 mg | Change at Day 2 | -1.14 | Standard Deviation 1.10 | Scores on a scale |
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Celecoxib 400/200 mg | Change at Day 2 | -1.23 | Standard Deviation 0.97 | Scores on a scale |
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Celecoxib 800/400 mg | Change at Day 2 | -1.51 | Standard Deviation 1.11 | Scores on a scale |
| Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity | Indomethacin 50 mg | Change at Day 2 | -1.62 | Standard Deviation 0.97 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 50 mg | Baseline | 2.39 | Standard Deviation 0.72 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 400/200 mg | Baseline | 2.15 | Standard Deviation 0.75 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 800/400 mg | Baseline | 2.26 | Standard Deviation 0.65 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Indomethacin 50 mg | Baseline | 2.13 | Standard Deviation 0.70 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 50 mg | Change at Day 5 | -1.44 | Standard Deviation 0.96 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 400/200 mg | Change at Day 5 | -1.39 | Standard Deviation 0.89 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 800/400 mg | Change at Day 5 | -1.58 | Standard Deviation 0.93 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Indomethacin 50 mg | Change at Day 5 | -1.52 | Standard Deviation 0.86 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 50 mg | Change at Day 9 | -1.75 | Standard Deviation 0.98 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 400/200 mg | Change at Day 9 | -1.64 | Standard Deviation 0.93 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Celecoxib 800/400 mg | Change at Day 9 | -1.84 | Standard Deviation 0.92 | Scores on a scale |
| Change From Baseline in Physician's Assessment of the Index Joint on Days 5, 9, and 14/Early Termination: Tenderness | Indomethacin 50 mg | Change at Day 9 | -1.65 | Standard Deviation 0.87 | Scores on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00549549/results